BMN 111
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Jan 13, 2014 → Oct 2, 2017
NCT ID
NCT02055157About BMN 111
BMN 111 is a phase 2 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02055157. Target conditions include Achondroplasia.
What happened to similar drugs?
0 of 3 similar drugs in Achondroplasia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03424018 | Phase 3 | Active |
| NCT02724228 | Phase 2 | Active |
| NCT02055157 | Phase 2 | Completed |
Competing Products
20 competing products in Achondroplasia